NEW YORK (GenomeWeb News) – Pharmacogenetic testing firm PGXL Laboratories announced on Thursday a long-term national distribution deal with Essential Molecular Testing for PGXL's drug sensitivity testing.
The partnership, called PGXL Partners, provides the Louisville, Ky.-based laboratory a larger sales force to address growing demand for its tests. In a statement, PGXL Labs President Roland Valdes Jr., said that the company has increased sales of its tests to thousands each month from hundreds.
The partnership between the two companies "began to take shape" in May and by the end of the year, more than 50,000 pharmacogenetic tests will have been ordered through PGXL Partners, PGXL Labs said. Its pharmacogenetic test menu includes CYP2C19, KRAS mutation detection, NAT2, and hepatitis B virus DNA quantitative assays.
Financial and other terms of the deal were not disclosed.
In August PGXL Labs and SureGene partnered to launch a five-gene test for determining which patients may be best candidates for the most widely used antipsychotics and antidepressants.